NCT04217473View on ClinicalTrials.gov

TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 26, 2020

Primary Completion Date

December 12, 2023

Study Completion Date

July 23, 2024

Conditions

Metastatic Melanoma

Interventions

BIOLOGICAL

TILT-123

TNFalpha and IL-2 coding oncolytic adenovirus TILT-123

Trial Locations (2)

Unknown

National Center for Cancer Immune Therapy Herlev Hospital, Copenhagen University, Copenhagen

CHU Nantes, Nantes

All Listed Sponsors

lead

TILT Biotherapeutics Ltd.

INDUSTRY

NCT04217473 - TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma | Biotech Hunter | Biotech Hunter